Beyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+574.64%
About This Group of Stocks
Our Expert Thinking
Leqembi's four-year success data validates the anti-amyloid approach to treating Alzheimer's disease. This breakthrough creates a ripple effect across the neurodegenerative treatment landscape, potentially de-risking similar therapies and attracting new investment capital to companies pursuing complementary strategies.
What You Need to Know
This group focuses on biotechnology companies at the forefront of Alzheimer's and neurodegenerative disease research. These stocks represent high-growth potential in a historically challenging but massive market, with companies developing next-generation therapies and diagnostic tools for early patient identification.
Why These Stocks
Each company was selected for its strategic alignment with the validated scientific mechanism behind Leqembi's success. These firms are developing treatments targeting amyloid or tau proteins, or creating advanced diagnostic tools necessary for the expanding Alzheimer's treatment market.
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 574.64% over the next year.
Stocks Rated Buy by Analysts
13 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Medical Breakthrough Momentum
Leqembi's four-year success data represents a historic breakthrough in Alzheimer's treatment. This validation could accelerate development timelines and attract significant new investment to the entire neurodegenerative disease sector.
Proven Science Opens Doors
The anti-amyloid approach is now validated with long-term data, potentially de-risking similar therapies in development. Companies with complementary strategies may see accelerated paths to market approval and investor confidence.
Massive Market Opportunity
The Alzheimer's treatment market represents billions in potential revenue as the global population ages. Early movers in this validated therapeutic approach could capture significant market share in this expanding healthcare sector.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Apple Onshoring Investment Theme Overview
Apple is investing $2.5 billion in its partner Corning to produce all iPhone and Apple Watch glass in the United States. This move highlights a growing trend of major corporations bringing manufacturing back to the U.S., creating opportunities for domestic high-tech suppliers.
Banking Consolidation Europe: Might UniCredit Spark Wave?
Italian banking giant UniCredit is considering the sale of its significant stake in Germany's Commerzbank, potentially to a buyer outside the European Union. This development could trigger a wave of consolidation and acquisition activity across the European banking sector, creating opportunities for strategic investors and advisory firms.
U.S.-China Trade Truce | Investment Opportunities
High-level talks between the U.S. and China are underway to prevent the return of tariffs, a critical step for global economic stability. This creates a potential investment opportunity in companies poised to benefit from improved trade relations and the removal of trade barriers.
Frequently Asked Questions
Everything you need to know about the product and billing.